Neuroblastoma: Biology, prognosis, and treatment

被引:217
作者
Park, Julie R. [1 ,2 ]
Eggert, Angelika [3 ]
Caron, Huib [4 ]
机构
[1] Univ Washington, Sch Med, Div Hematol & Oncol, Seattle, WA 98105 USA
[2] Childrens Hosp & Reg Med Ctr, Seattle, WA 98105 USA
[3] Univ Childrens Hosp Essen, Dept Hematol Oncol, D-45122 Essen, Germany
[4] Emma Childrens Hosp AMC, Dept Pediat Oncol & Hematol, EKZ AMC, NL-1100 DE Amsterdam, Netherlands
关键词
D O I
10.1016/j.pcl.2007.10.014
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Neuroblastoma, a neoplasm of the sympathetic nervous system, is the second most common extracranial malignant tumor of childhood and the most common solid tumor of infancy. Neuroblastoma is a heterogeneous malignancy with prognosis ranging from near uniform survival to high risk for fatal demise. Neuroblastoma. serves as a paradigm for the prognostic utility of biologic and clinical data and the potential to tailor therapy for patient cohorts at low, intermediate, and high risk for recurrence. This article summarizes our understanding of neuroblastoma biology and prognostic features and discusses their impact on current and proposed risk stratification schemas, risk-based therapeutic approaches, and the development of novel therapies for patients at high risk for failure.
引用
收藏
页码:97 / +
页数:25
相关论文
共 126 条
[1]   Efficacy of complete resection for high-risk neuroblastoma: A children's cancer group study [J].
Adkins, ES ;
Sawin, R ;
Gerbing, RB ;
London, WB ;
Matthay, KK ;
Haase, GM .
JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (06) :931-936
[2]   Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma [J].
Albertini, MR ;
Gan, J ;
Jaeger, P ;
Hank, JA ;
Storer, B ;
Schell, K ;
Rivest, T ;
Surfus, J ;
Reisfeld, RA ;
Schiller, JH ;
Sondel, PM .
JOURNAL OF IMMUNOTHERAPY, 1996, 19 (04) :278-295
[3]   Notch signaling in cancer [J].
Allenspach, EJ ;
Maillard, I ;
Aster, JC ;
Pear, WS .
CANCER BIOLOGY & THERAPY, 2002, 1 (05) :466-476
[4]  
Almgren MAE, 2004, MOL CANCER RES, V2, P387
[5]  
ALTMAN AJ, 1976, CANCER, V37, P846, DOI 10.1002/1097-0142(197602)37:2<846::AID-CNCR2820370233>3.0.CO
[6]  
2-L
[7]   Natural history and biology of Stage A neuroblastoma: A Pediatric Oncology Group study [J].
Alvarado, CS ;
London, WB ;
Look, AT ;
Brodeur, GM ;
Altmiller, DH ;
Thorner, PS ;
Joshi, VV ;
Rowe, ST ;
Nash, MB ;
Smith, EI ;
Castleberry, RP ;
Cohn, SL .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2000, 22 (03) :197-205
[8]  
[Anonymous], 1989, Pathology of tumours of the nervous system, ed
[9]   Human neuroblastomas with unfavorable biologies express high levels of brain-derived neurotrophic factor mRNA and a variety of its variants [J].
Aoyama, M ;
Asai, K ;
Shishikura, T ;
Kawamoto, T ;
Miyachi, T ;
Yokoi, T ;
Togari, H ;
Wada, Y ;
Kato, T ;
Nakagawara, A .
CANCER LETTERS, 2001, 164 (01) :51-60
[10]   Chromosome 1p and 11q deletions and outcome in neuroblastoma [J].
Attiyeh, EF ;
London, WB ;
Mossé, YP ;
Wang, Q ;
Winter, C ;
Khazi, D ;
McGrady, PW ;
Seeger, RC ;
Look, AT ;
Shimada, H ;
Brodeur, GM ;
Cohn, SL ;
Matthay, KK ;
Maris, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21) :2243-2253